Cencora Inc. closed $1.59 short of its 52-week high ($251.56), which the company reached on November 12th. Supported by world ...

Shares have been on the move with the stock up 6.7% over the past month. The stock hit a new 52-week high of $251.56 in the previous session. Cencora has gained 21.1% since the start of the year ...

Leading medical distributors McKesson (NYSE:MCK) and Cencora (NYSE:COR) will have to pay $266M in damages to Baltimore after ...

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Cencora (COR – Research Report), with a price ...

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles ...

Drug distributor Cencora plans to buy Retina Consultants of America from Webster Equity Partners in a $4.6 billion deal.  | ...

The company enhanced its strategic pharmaceutical distribution capabilities and expanded its specialty services with the acquisition of Retina Consultants Cencora (COR) announced that it has ...

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual US healthcare distribution sales, the company ...

Summit Global Investments acquired a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the 3rd quarter, ...

Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028.

Cherny now forecasts that the company will post earnings of $3.45 per share for the quarter, up from their previous estimate of $3.43. The consensus estimate for Cencora’s current full-year ...

Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 ...